



## BRENTUXIMAB VEDOTIN

An investigational  
antibody-drug conjugate  
directed to CD30

### Anti-CD30 monoclonal antibody


Chimeric IgG1  
antibody that binds  
to human CD30

### MMAE

Microtubule-disrupting  
agent

### Protease-cleavable mc-vc linker

Covalently attaches  
MMAE to the antibody  
and releases agent  
within the target cell



### Target: CD30

- CD30 is expressed in many B- and T-cell lymphomas while having limited expression in normal tissue<sup>1</sup>

### Proposed Mechanism of Action<sup>2-12,a</sup>

- Direct cytotoxicity
- Bystander effect
- Immunogenic cell death
- Antibody-dependent cellular phagocytosis

**CD:** cluster of differentiation; **IgG1:** immunoglobulin G1; **mc-vc:** maleimidocaproyl-valine-citrulline; **MMAE:** monomethyl auristatin E

<sup>a</sup>Based on preclinical data

1. Wahl AF. Cancer Res. 2002; 3736-42. 2. ADCETRIS. Prescribing information. Seagen Inc.; 2022. 3. Gardai SJ. Cancer Res. 2015; Abstract 2469. 4. Muller P. Cancer Immunol Res. 2014; 741-55. 5. Oflazoglu E. Blood. 2007; 4370-2. 6. Gardai SJ. Haematologica. 2016; Abstract P099. 7. van de Donk NW. MAbs. 2012; 458-65. 8. Okeley NM. Clin Cancer Res. 2010; 888-97. 9. Li F. AACR 2014; Abstract 3694. 10. Piccaluga PP. Adv Hematol. 2011; 920898. 11. Cao A. Immunology. 2016; 4914. 12. Heiser RA. AACR 2018; Abstract 18-A-5588-AACR.

**The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.**



Scan to learn more about the proposed mechanism of action of brentuximab vedotin

Clinical Trials<sup>a</sup>

Phase 1 Phase 2 Phase 3



**RECRUITING** ECHELON-3: Relapsed/refractory diffuse large B-cell lymphoma (NCT04404283) Brentuximab vedotin + lenalidomide and rituximab vs placebo + lenalidomide and rituximab



**ACTIVE, NOT RECRUITING** SGN35-015: Frontline Hodgkin lymphoma or CD30+ PTCL in older patients with significant comorbidities ineligible for standard chemotherapy (NCT01716806) Brentuximab vedotin



**ACTIVE, NOT RECRUITING** SGN35-027: Frontline early- and advanced-stage Hodgkin lymphoma (NCT03646123) A + AVD with G-CSF primary prophylaxis or AN + AD



**RECRUITING** SGN35-032: Frontline PTCL with CD30-low and -negative expression (NCT04569032) Brentuximab vedotin + CHP



**RECRUITING** SGN35-033: Metastatic solid tumors after progression on PD-1 inhibitor treatment (NCT04609566) Brentuximab vedotin + pembrolizumab



**ACTIVE, NOT RECRUITING** CheckMate 744: Relapsed/refractory classical Hodgkin lymphoma in AYA patients (NCT02927769) Brentuximab vedotin + nivolumab

A + AVD: brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; AN + AD: brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine; AYA: adolescents and young adults; CD: cluster of differentiation; CHP: cyclophosphamide, doxorubicin, and prednisone; G-CSF: granulocyte colony stimulating factor; PD-1: programmed cell death protein 1; PTCL: peripheral T-cell lymphoma

<sup>a</sup>Program being developed in collaboration with Takeda Pharmaceutical Company, Ltd.

Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.